The recently published Ez-PAVE trial has further consolidated one of the fundamental principles of cardiovascular prevention by demonstrating that an intensive low-density lipoprotein cholesterol (LDL-C) target (<55 mg/dL) is associated with a lower incidence of major cardiovascular events than a conventional target (<70 mg/dL) in patients with established atherosclerotic cardiovascular disease [1]. Together with the evidence generated by the FOURIER and ODYSSEY OUTCOMES trials, these findings reinforce the paradigm that "lower is better" and support increasingly intensive lipid-lowering strategies in patients at very high cardiovascular risk [2,3].
